1404115-38-3

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
(2-bromo-3,6-difluorophenyl)methanol is used as a building block in the synthesis of pharmaceuticals and agrochemicals for its unique structural features and properties.
Used in Organic Compounds and Materials Production:
(2-bromo-3,6-difluorophenyl)methanol is used in the production of various organic compounds and materials due to its versatile chemical structure.
Used in Medicinal Chemistry and Drug Discovery:
(2-bromo-3,6-difluorophenyl)methanol has potential applications in the field of medicinal chemistry and drug discovery, where its unique structural features and properties can be utilized for developing new therapeutic agents.
It is important to handle (2-bromo-3,6-difluorophenyl)methanol with care as it may pose health and environmental risks if not properly managed.

Upstream product

• 934987-26-5 2-bromo-3,6-difluoro-benzaldehyde 

Downstream Products

• 1404115-42-9 C₁₃H₁₆BrF₂NO₂ 
• 1380021-30-6 C₈H₈BrF₂N 
• 1256482-82-2 C₈H₄BrF₂N 

Relevant academic research and scientific papers

HIF-2α INHIBITORS FOR TREATING IRON OVERLOAD DISORDERS

The present disclosure relates to HIF-2α inhibitors and methods of making and using them for treating iron overload disorders. Certain compounds were potent in HIF-2α scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and reduced liver iron accumulation and serum iron parameters in both prophylactic and treatment mouse models.

CYCLIC SULFONE AND SULFOXIMINE ANALOGS AND USES THEREOF

The present disclosure relates to cyclic sulfones and sulfoximines that are HIF-2a inhibitors and methods of making and using them for treating cancers. In another aspect, the present disclosure provides a pharmaceutical composition comprising a compound described herein and a pharmaceutically acceptable carrier or excipient. The compound may exist in an amorphous form, a crystalline form, or as a salt, solvate, or hydrate. In another aspect, the present disclosure provides a method of treating renal cell carcinoma by administrating a therapeutically effective amount of a compound described herein or a pharmaceutical composition thereof to a subject in need of such treatment.

Phenethyl nicotinamides, a novel class of NaV1.7 channel blockers: Structure and activity relationship

The NaV1.7 ion channel is an attractive target for development of potential analgesic drugs based on strong genetic links between mutations in the gene coding for the channel protein and inheritable pain conditions. The (S)-N-chroman-3-ylcarboxamide series, exemplified by 1, was used as a starting point for development of new channel blockers, resulting in the phenethyl nicotinamide series. The structure and activity relationship for this series was established and the metabolic issues of early analogues were addressed by appropriate substitutions. Compound 33 displayed acceptable overall in vitro properties and in vivo rat PK profile.